| abstract |
Eribulin, or a pharmaceutically acceptable salt thereof, for use in the treatment of certain breast cancers. The method is selected as having (i) HER2-negative breast cancer, (ii) estrogen receptor (ER) -negative breast cancer, or (iii) HER2-negative, ER-negative and progesterone receptor (PR) negative (triple-negative) breast cancer. Eribulin or a pharmaceutically acceptable salt thereof for use in the treatment of breast cancer in a subject. 【Selection chart】 None |